PRME
Prime Medicine, Inc.
$3.78
-0.45 (-10.64%)
At close · Jul 10
Market Cap
$682.73M
Shares
180,617,451
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.78
Open$4.20
Day$3.62–4.27
52W$2.67–6.94
Avg vol 30d3.9M
Short int34.7M · 19.2% float · 9.1d
Short vol60%
Last earningsNov 12, 2025
DataOct 2022–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
+14%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
26%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+39%
trailing
6-month return
−5%
trailing
YTD return
+9%
this year
Relative strength
−14%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
2 of 192 funds reported for Jun 30 · net +73 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.23% of float · ▲ +6.7% MoM · 9.1 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
192 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+55%
Y/Y
EPS growth
+18%
Y/Y
Free cash flow
$-167.1M
Balance sheet
$63.0M
net cash
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
10.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
+14%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
26%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
2 of 192 funds reported for Jun 30 · net +73 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
19.23% of float · ▲ +6.7% MoM · 9.1 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
192 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $4 · 26%
52-wk high $7
vs 200-day avg -3%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRME
this stock
Prime Medicine, Inc.
|
$682.73M | +8.9% | — | — | 19.2% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRME | -2.3% | +39.5% | -5.3% | +2.4% | +8.9% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -3.7% | +35.4% | -14.3% | +1.3% | -1.8% |